Liquid chromatography–tandem mass spectrometry (LC–MS/MS) reveals distinct sphingolipid patterns in anorexia and obesity.
|Articles|February 1, 2008
- The Application Notebook-02-01-2008
- Volume 0
- Issue 0
On-Line Sample Clean-Up for the LC/MS Analysis of Small Molecules in Serum
Articles in this issue
almost 19 years ago
Is Bottled Nitrogen a Greenhouse Gas?almost 19 years ago
Accurate, Reliable Fractionation of Extractable Petroleum Hydrocarbonsalmost 19 years ago
Analysis of Essential Oil Enantiomers by Chiral GCxGC-TOFMSalmost 19 years ago
Fast, Accurate Semivolatiles Analysis Using Rxi-5Sil MS Capillary GC Columnsalmost 19 years ago
GC-MS with a DART Ion SourceRelated to this article
Leon Niezen and Gert Desmet discuss uncertainty-driven LC method development, peak overlap, and moving from in silico to real data.
Leon Niezen and Gert Desmet describe how predictive uncertainty can make automated LC method development more reliable.
Liquid chromatography–mass spectrometry (LC–MS) serum profiling ties lysine compounds to lupus kidney disease.
Liquid chromatography-mass spectrometry (LC–MS) growth lifts Waters Q3; MOBILion ion mobility buy expands proteomics.
Liquid chromatography–tandem mass spectrometry (LC–MS/MS) measures galactose-1-phosphate in dried blood spots to monitor galactosemia.
Sam Whitmarsh explores how retention-time models handle interlaboratory data, novel chemotypes, unusual phases and ionisable compounds, and what labs need to do to build useful in-house models.
Trending on LCGC International
1
AI/ML Now: Toxicity Prediction for Unknown LC–HRMS Features Using Machine Learning
2
LCGC Blog: Building a Career Series That Goes Beyond the Surface
3
Industry Roundup: Waters Posts Strong Third Quarter as LC–MS and Chromatography Consumables Drive Growth, Acquires Ion Mobility Pioneer MOBILion
4
From 9000 Clues to a Clinical Test: Mass Spectrometry-Driven Lipidomics for Early Cancer Detection
5